NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage developer of antiviral drugs, has announced that its Phase II clinical trial evaluating NV-387 Oral Gummies as a treatment for Bundibugyo ebolavirus and other Ebola viruses has been registered in the Pan African Clinical Trials Registry under identification number PACTR202608748555077. The trial will take place in the Democratic Republic of Congo (DRC), where the company has already received local regulatory approval from ACOREP to begin the study.
The registration marks a critical milestone for the company as it prepares to dose the first patients within one to two weeks, barring any outbreak-related impediments. NanoViricides has confirmed that NV-387 has been delivered to the clinical trial site in Ituri province. The adaptive trial design will begin with a single-arm safety and dose run-in phase, followed by a randomized, controlled, open-label efficacy evaluation.
NV-387 is an orally administered broad-spectrum antiviral designed to mimic host-side features that viruses require for infection. This mechanism is intended to neutralize a wide range of viruses, making it a promising candidate not only for Ebola but also for other viral threats. The drug is currently being evaluated in another Phase II clinical trial for Mpox in the DRC, underscoring its potential as a versatile antiviral agent.
The importance of this trial extends beyond NanoViricides. Ebola outbreaks in the DRC have historically posed significant public health challenges, with high mortality rates and limited treatment options. The development of an oral antiviral that can be easily administered in resource-limited settings could dramatically improve outbreak response capabilities. Current treatments for Ebola, such as intravenous monoclonal antibodies, require cold chain logistics and trained medical personnel, which are often scarce in remote outbreak zones. An oral formulation like NV-387 could be distributed more widely and administered more readily, potentially reducing transmission and saving lives.
Dr. Anil Diwan, President and Executive Chairman of NanoViricides, has previously emphasized the company’s commitment to addressing urgent global health threats. The registration of this trial demonstrates progress in that mission, as the company leverages its proprietary nanoviricide technology platform to develop broad-spectrum antivirals. The technology, based on intellectual property licensed from TheraCour Pharma, Inc., involves creating specially engineered nanomaterials that mimic host cell receptors, thereby attracting viruses and neutralizing them.
The adaptive trial design is particularly noteworthy. By starting with a safety run-in, researchers can closely monitor the drug’s tolerability and adjust dosing before proceeding to the efficacy phase. This approach is efficient and allows for early detection of any safety concerns, which is crucial in a high-stakes disease like Ebola.
However, the path to approval is long and capital-intensive. NanoViricides acknowledges that there can be no assurance that NV-387 will demonstrate sufficient effectiveness and safety in human trials. The company faces typical risks associated with drug development, including potential setbacks in clinical trials and regulatory hurdles. Nevertheless, the registration of this trial marks a step forward in the fight against Ebola and other viral diseases.
For more information about NanoViricides and its pipeline, visit the company’s newsroom at https://nnw.fm/NNVC.
